Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News

Evidence builds for AFib ablation’s efficacy in heart failure
- Author:
- Mitchel L. Zoler, PhD
Data from the CABANA trial and recent meta-analyses add evidence for AFib ablation in selected heart failure...
News

FDA panel supports Vascepa expanded indication for CVD reduction
- Author:
- Mitchel L. Zoler, PhD
Icosapent ethyl (Vascepa), purified eicosapentaenoic acid, got unanimous support from an FDA panel for a new indication of reducing CVD events.
News

ATTEST: AFib ablation slows progression to persistence
- Author:
- Mitchel L. Zoler, PhD
PARIS – AFib ablation cut the rate of paroxysmal to persistent arrhythmia progression by 89%, compared with medical management in a randomized...
News

Bariatric surgery as safe in adolescents as it is in adults
- Author:
- Mitchel L. Zoler, PhD
Sleeve gastrectomy was significantly safer during the perioperative and immediate postoperative periods, compared with gastric bypass.
News

Bariatric surgery shows metabolic benefits in lower-BMI patients
- Author:
- Mitchel L. Zoler, PhD
LAS VEGAS – Data from 45,000 patients showed that those who had a BMI below 35 kg/m2 benefited as much as those with higher BMIs.
News

Previously healthy patients hospitalized for sepsis show increased mortality
- Author:
- Mitchel L. Zoler, PhD
WASHINGTON – U.S. patients hospitalized with community-acquired sepsis had higher mortality when they had no other comorbidities.
News

Sacubitril/valsartan suggests HFpEF benefit in neutral PARAGON-HF
- Author:
- Mitchel L. Zoler, PhD
PARIS – PARAGON-HF’s primary endpoint was neutral, but desperation for a HFpEF therapy highlights a subgroup analysis.
News

Birth year linked to influenza-subtype susceptibility
- Author:
- Mitchel L. Zoler, PhD
Analysis of a recent U.S. flu season showed some age groups were more prone to get H1N1 flu, while H3N2 predominated at other ages.
News

FDA proposes new breast implant labeling with a boxed warning
- Author:
- Mitchel L. Zoler, PhD
Following a high-profile hearing in March 2019, and a textured breast implant recall in July, the FDA has proposed a boxed warning and other...
News

One monoclonal dose gives preterm neonates season-long RSV protection
- Author:
- Mitchel L. Zoler, PhD
A single monoclonal antibody dose cut respiratory syncytial virus infection in healthy preterm infants for 150...
News

Cell culture–based flu vaccine maintains immunogenicity
- Author:
- Mitchel L. Zoler, PhD
A 2018-2019 commercial flu vaccine made mostly by egg-free cell culture performed as well immunologically as standard vaccine.
News

In utero Zika exposure can have delayed consequences
- Author:
- Mitchel L. Zoler, PhD
Infants born following in utero Zika virus exposure can appear normal at birth but have neurodevelopmental problems later.
News

Valacyclovir safely cut vertical CMV transmission
- Author:
- Mitchel L. Zoler, PhD
A single-center, randomized study showed 8 g/day valacyclovir safely reduced CMV passage from mothers to their fetuses.
News

Oral drug cut viral respiratory tract infections in elderly
- Author:
- Mitchel L. Zoler, PhD
WASHINGTON – Once-daily dosing with RTB101 safely dropped viral respiratory tract infections in elderly people...
Video

Beta-blockers effective, safe for HFrEF with renal dysfunction
- Author:
- Mitchel L. Zoler, PhD
PARIS – Meta-analysis of more than 17,000 heart failure patients showed efficacy and safety of beta-blockers in...